Published in Surg Today on August 28, 2008
CD28 family and chronic rejection: "to belatacept...And beyond!". J Transplant (2012) 0.82
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. Ther Deliv (2011) 0.81
Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target. Transplantation (2013) 0.78
Costimulation blockade inhibits the indirect pathway of allorecognition in nerve allograft rejection. Muscle Nerve (2011) 0.78
ICOS Co-Stimulation: Friend or Foe? Front Immunol (2016) 0.77
Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage library. MAbs (2009) 0.76
Inducible costimulatory molecule deficiency induced imbalance of Treg and Th17/Th2 delays rejection reaction in mice undergoing allogeneic tracheal transplantation. Am J Transl Res (2014) 0.75
Current status of and prospects for the English medical journal Surgery Today. Surg Today (2010) 0.75
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
CD28/B7 system of T cell costimulation. Annu Rev Immunol (1996) 10.48
A cell culture model for T lymphocyte clonal anergy. Science (1990) 9.86
Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg (1969) 8.26
A theory of self-nonself discrimination. Science (1970) 7.99
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 6.61
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 5.76
ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature (2001) 5.32
T-cell co-stimulation through B7RP-1 and ICOS. Nature (1999) 4.20
Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med (2000) 3.84
Heavy metal intensification of DAB-based HRP reaction product. J Histochem Cytochem (1981) 3.53
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A (1997) 3.25
T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A (1992) 2.98
The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity (2000) 2.70
A technique for accessory cervical heart transplantation in rabbits and rats. Acta Pathol Microbiol Scand A (1971) 2.55
A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci (1975) 2.33
Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol (2000) 2.17
Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med (2001) 2.17
Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol (2001) 2.10
ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol (2001) 1.85
Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154. Proc Natl Acad Sci U S A (1999) 1.79
The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol (2001) 1.74
Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci U S A (1993) 1.72
The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev (1998) 1.68
Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. Transplantation (2005) 1.41
ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine secretion by memory CD4+ T cells. Proc Natl Acad Sci U S A (2002) 1.28
Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunol (2001) 1.27
The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest (2003) 1.26
Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol (2000) 1.25
The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol (2000) 1.20
CD28-independent costimulation of T cells in alloimmune responses. J Immunol (2001) 1.16
Morphology of solid organ allograft arteriopathy: identification of proliferating intimal cell populations. Transplant Proc (1989) 1.12
CD28-independent induction of T helper cells and immunoglobulin class switches requires costimulation by the heat-stable antigen. J Exp Med (1998) 1.09
Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol (2002) 1.04
Pathology and etiology of chronic rejection of the heart. Clin Transplant (1994) 1.02
Prolonged cardiac allograft survival in rats systemically injected adenoviral vectors containing CTLA4Ig-gene. Transplantation (1999) 0.89
ICOS contributes to T cell expansion in CTLA-4 deficient mice. J Immunol (2005) 0.87
Prolonged survival in rat liver transplantation with mouse monoclonal antibody against an inducible costimulator (ICOS). Transplantation (2002) 0.86
AILIM/ICOS: its expression and functional analysis with monoclonal antibodies. Hybrid Hybridomics (2001) 0.82
Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. Transplantation (2005) 0.81
In vitro analysis of CD40-CD154 and CD28-CD80/86 interactions in the primary T-cell response to allogeneic "nonprofessional" antigen presenting cells. Transplantation (2001) 0.78
AdCTLA-4Ig combined with donor splenocytes, bone marrow cells and anti-ICOS antibody treatment induce tolerance in a rat heart transplantation model. Transpl Int (2003) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med (2002) 4.25
Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13
Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics (2005) 3.93
One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol (2006) 2.59
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
3D cell nuclei segmentation based on gradient flow tracking. BMC Cell Biol (2007) 2.41
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res (2004) 2.34
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
Portal uptake function in veno-occlusive regions evaluated by real-time fluorescent imaging using indocyanine green. J Hepatol (2012) 2.27
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun (2002) 2.13
Living donor liver transplantation: the Asian perspective. Transplantation (2014) 2.13
Regeneration and function of hemiliver graft: right versus left. Surgery (2006) 2.12
Brain tissue segmentation based on DTI data. Neuroimage (2007) 2.06
Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections. World J Surg (2004) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg (2003) 2.01
Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg (2003) 2.00
Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics (2008) 1.99
Genomic analysis of the immune gene repertoire of amphioxus reveals extraordinary innate complexity and diversity. Genome Res (2008) 1.92
Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol (2006) 1.89
Robust deformable-surface-based skull-stripping for large-scale studies. Med Image Comput Comput Assist Interv (2011) 1.88
The vessel sealing system (LigaSure) in hepatic resection: a randomized controlled trial. Ann Surg (2009) 1.87
Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg (2007) 1.82
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol (2010) 1.79
Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2006) 1.78
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
DICCCOL: dense individualized and common connectivity-based cortical landmarks. Cereb Cortex (2012) 1.78
An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med (2014) 1.76
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther (2003) 1.73
Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol (2006) 1.72
Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery (2003) 1.67
Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl (2012) 1.64
Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis (2007) 1.60
Comparative metagenomics of microbial communities inhabiting deep-sea hydrothermal vent chimneys with contrasting chemistries. ISME J (2010) 1.60
GM130, a cis-Golgi protein, regulates meiotic spindle assembly and asymmetric division in mouse oocyte. Cell Cycle (2011) 1.60
Refinement of venous reconstruction using cryopreserved veins in right liver grafts. Liver Transpl (2004) 1.59
One orifice vein reconstruction in left liver plus caudate lobe grafts. Transplantation (2007) 1.57
Clinical significance of extrahepatic bile duct resection for advanced gallbladder cancer. J Surg Oncol (2006) 1.56
Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation (2007) 1.56
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford) (2011) 1.56
Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg (2005) 1.56
Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer (2003) 1.54
The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol (2005) 1.52
Portal vein complications after adult-to-adult living donor liver transplantation. Transpl Int (2008) 1.51
Systematic grading of morbidity after living donation for liver transplantation. Gastroenterology (2008) 1.51
Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol (2003) 1.50
Transfusion criteria for fresh frozen plasma in liver resection: a 3 + 3 cohort expansion study. Arch Surg (2011) 1.50
Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg (2002) 1.49
Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int (2014) 1.49
Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma. J Gastroenterol (2004) 1.48
Applicability of enhanced recovery program for advanced liver surgery. World J Surg (2014) 1.48
Optimization of functional brain ROIs via maximization of consistency of structural connectivity profiles. Neuroimage (2011) 1.46
Ultrasonically assisted retrohepatic dissection for a liver hanging maneuver. Ann Surg (2005) 1.46
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol (2010) 1.44
Lower incidence of biliary carcinoma in patients with primary sclerosing cholangitis and high serum levels of immunoglobulin E. Clin Gastroenterol Hepatol (2011) 1.44
Review of methods for functional brain connectivity detection using fMRI. Comput Med Imaging Graph (2008) 1.44
Hepatic arterial anatomy for right liver procurement from living donors. Liver Transpl (2004) 1.44
Evaluation of hepatic venous congestion: proposed indication criteria for hepatic vein reconstruction. Ann Surg (2002) 1.43
Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer (2005) 1.42
Reconstruction of central cortical surface from brain MRI images: method and application. Neuroimage (2007) 1.42
Two-stage pancreatojejunostomy in pancreaticoduodenectomy: a retrospective analysis of short-term results. Am J Surg (2008) 1.41
Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma (2010) 1.41
Bile duct preserving surgery for hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg (2015) 1.41
Could we or should we replace the conventional nomenclature of liver resections? Ann Surg (2013) 1.40
Next-generation sequencing in the clinic: promises and challenges. Cancer Lett (2012) 1.39
Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg (2004) 1.37
Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol (2009) 1.35